Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
06/23 DAIICHI SANKYO : ProLynx collaborates with Daiichi Sankyo on drug delivery
06/22 OSCAR INVESTMENTS : High court tells former ranbaxy promoters to maintain value ..
06/20 DAIICHI SANKYO : ProLynx announces collaboration with Daiichi Sankyo to evaluate..
06/09 DAIICHI SANKYO : New Findings on Inflammation Mediators Described by Investigato..
06/09 DAIICHI SANKYO : Studies from Daiichi Sankyo Have Provided New Data on Medicinal..
06/09 DAIICHI SANKYO : and Inspirion Delivery Sciences LLC Announce Plans for Commerci..
06/01 DAIICHI SANKYO : Cancer Enterprise Pipeline Data Showing Swift Progress in Preci..
05/18 DAIICHI SANKYO : Data on Carboxylic Ester Hydrolases Reported by Researchers at ..
05/11 NEW ANTIBIOTICS STUDY FINDINGS HAVE : biological...
05/11 DAIICHI SANKYO : Researchers at Daiichi Sankyo Report New Data on Toxicology (Co..
More news
Sector news : Pharmaceuticals - NEC
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/13 FDA's Gottlieb taking aim at opioid epidemic, wants post-market studies to co..
06/09 KemPharm on deck to present data on hydromorphone prodrug KP511
05/30 Daiichi Sankyo to lead U.S. commercialization of Inspirion's abuse-deterrent ..
05/11 Daiichi Sankyo reports FY results
05/10 Pieris Blooms With Astra Deal
Advertisement
Financials ( JPY)
Sales 2018 917 993 M
EBIT 2018 -
Net income 2018 67 684 M
Finance 2018 354 461 M
Yield 2018 2,75%
P/E ratio 2018 25,15
P/E ratio 2019 27,61
EV / Sales 2018 1,58x
EV / Sales 2019 1,70x
Capitalization 1 807 979 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 434  JPY
Spread / Average Target -4,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..6.58%16 184
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
MERCK AND COMPANY11.98%180 958
More Results